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Abstract 
 
Cohesin is required for ES cell self-renewal and iPS-mediated reprogramming of somatic 
cells. This may indicate a special role for cohesin in the regulation of pluripotency genes, 
perhaps by mediating long-range chromosomal interactions between gene regulatory 
elements. However, cohesin is also essential for genome integrity, and its depletion from 
cycling cells induces DNA damage responses. Hence, the failure of cohesin-depleted cells to 
establish or maintain pluripotency gene expression could be explained by a loss of long-
range interactions or by DNA damage responses that undermine pluripotency gene 
expression. In recent work we began to disentangle these possibilities by analysing 
reprogramming in the absence of cell division. These experiments showed that cohesin was 
not specifically required for reprogramming, and that the expression of most pluripotency 
genes was maintained when ES cells were acutely depleted of cohesin. Here we take this 
analysis to its logical conclusion by demonstrating that deliberately inflicted DNA damage - 
and the DNA damage that results from proliferation in the absence of cohesin - can directly 
interfere with pluripotency and reprogramming. The role of cohesin in pluripotency and 
reprogramming may therefore be best explained by essential cohesin functions in the cell 
cycle. 
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Introduction: 
 
Several studies reported an essential role for cohesin in ES cell self-renewal and in the iPS-
mediated reprogramming of somatic cells to pluripotency.1–4 Given that in mammalian cells 
cohesin associates with CTCF, 5–8 NIPBL, Mediator and cell-type specific transcription 
factors1,9,10 at gene regulatory elements and can mediate long-range chromosomal 
interactions,1–4,11–16 these data suggested a special place for cohesin in the network of 
pluripotency where it enables the expression of pluripotency genes by forming connections 
between their regulatory elements. 
 
However, cohesin has essential functions in preserving the integrity of the genome through 
the cell cycle. Cohesin consists of a heterodimer of SMC (structural maintenance of 
chromosomes) proteins - SMC1A and SMC3, and two non-SMC proteins - RAD21 and either 
STAG1 or STAG2 and forms a ring-like structure with a diameter of 40 nm. This is large 
enough to topologically entrap two strands of nucleosomal DNA.17,18 Cohesin's association 
with chromatin is carefully regulated during the cell cycle to facilitates its cell cycle-
dependent and cell cycle-independent functions19 (Figure 1A). In vertebrate cells, cohesin 
loading onto DNA is initiated in telophase20,21 and requires the activity of the cohesin loading 
factor NIPBL and its partner MAU2.22–24 During interphase, cohesin association with DNA is 
maintained in a dynamic equilibrium by the opposing unloading actions of the WAPL and 
PDS5 proteins.25 Current models suggest that cohesin acts as a transcriptional regulator and 
genome organiser by forming chromatin interactions between distant DNA regions.26,27  
Locally, cohesin mediated enhancer-promoter interactions facilitate the rearrangement of the 
T cell receptor alpha chain locus Tcra in non-proliferating thymocytes12. On a global scale, 
cohesin associated with CTCF at the boundaries of topologically associating domains 
(TADs) is important for the structural organisation of the genome. Loss of cohesin allows 
increased inter-domain interactions across TAD boundaries28 and while architectural 
chromatin compartments are not affected, cohesin is required for specific interactions within 
the compartments.29 In S phase, cohesin facilitates DNA replication.30–32 The acetylation of 
SMC3 by ESCO1/2 establishes stable cohesin binding to DNA.33,34 Once stably bound, 
cohesin holds the sister chromatids together until they segregate during mitosis. The 
proximity of replicated DNA strands provided by cohesin also enables homology-based 
repair of post-replicative DNA lesions.35,36 After the onset of mitosis, most of the cohesin 
associated with chromosome arms is removed by the prophase pathway and the small 
fraction of cohesin retained at centromeres allows the continued alignment of chromosomes 
at the metaphase plate following spindle attachment. Cleavage of centromeric cohesin by 
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separase at the onset of anaphase then facilitates the segregation of sister chromatids to 
daughter cells.37  
 
RNAi-mediated knockdown has been widely used to probe cohesin's role in gene regulation, 
and RNAi screens identified cohesin as a factor required for the self-renewal of pluripotent 
embryonic stem (ES) cells.1,38–40 However, gene expression analysis in ES cells 5 days after 
cohesin knockdown 1 revealed a preferential deregulation of genes related to cell cycle and 
DNA damage.41 Prolonged depletion of cohesin from rapidly dividing ES or iPS cells can 
therefore result in DNA damage, checkpoint activation, cell cycle arrest and the induction of 
p53 target gene expression (Figure 1B). In turn, DNA damage responses abolish 
pluripotency gene expression42–44 and reprogramming.45–47  Hence, failure to establish or 
maintain pluripotency gene expression in cohesin-depleted cells does not necessarily 
implicate a loss of long-range interactions, but suggests the possibility that DNA damage 
responses could have interfered with pluripotency gene expression. 
 
In a recent study we began to disentangle DNA damage responses from long-range 
interactions by conducting reprogramming experiments in the absence of cell division. 
Fusion of ES cells with somatic cells generates heterokaryons, which initiate reprogramming 
without cell division. In addition, nuclear transfer experiments eliminate the requirement for 
DNA replication. These experiments indicated that cohesin was not specifically required for 
reprogramming, and that ES cells maintained the expression of most pluripotency genes 
when analysed after cohesin depletion but before the onset of DNA damage responses.41 
Here we take this analysis to its logical conclusion by showing that deliberately inflicted DNA 
damage - or the DNA damage resulting from prolonged cohesin depletion in cycling ES cells 
- actively interferes with pluripotency and reprogramming. Our findings suggest that data 
concerning the role of cohesin in pluripotency and reprogramming derived from cells that 
cycle in the absence of cohesin should be re-interpreted in the context of essential cohesin 
functions in the cell cycle. 
 
Results 
 
A simple but restrictive approach to dissociate cell cycle-related and gene regulatory 
functions of cohesin is the genetic deletion of depletion of cohesin from non-cycling 
cells12,28,48 . Alternatively, cohesin can be acutely depleted from cycling cells at the gene 
level (by inducible deletion) or the protein level (by inducible cleavage or degradation), 
provided that depletion is sufficiently rapid to occur within a single cell cycle. Our 
experiments combined inducible ERt2Cre and conditional Rad21 alleles 41 to efficiently 
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deplete mRNA (Figure 2A) and protein (Figure 2B) in ES cells within 24h of ERt2Cre 
induction by 4-hydroxy tamoxifen. This was achieved without significant induction of DNA 
damage (as indicated by phosphorylation of histone H2AX, γ-H2AX, Fig 2C) and in the 
absence of p53-dependent stress responses (such as Mdm2 induction, Figure 2D) or cell 
cycle arrest (Figure 2E). 
 
Genome-wide transcriptional profiling showed that ~600 genes were deregulated. These 
genes were enriched for developmental functions but not for cell cycle or DNA damage 
responses. Deregulated expression was highly correlated with cohesin binding by ChIP-seq, 
indicating that many deregulated genes were direct targets of cohesin. 41 Quantitative 
reverse transcription PCR (RT-PCR) of selected pluripotency markers confirmed our array 
data indicating that the expression of Nanog remained unaffected, Klf4 was downregulated 
and Lefty1 was upregulated (Figure 2F). Overall, 8% of deregulated genes were 
pluripotency-associated (Figure 2G) and 12% of pluripotency genes were affected by 
cohesin depletion. Hence, acute cohesin depletion in ES cells did not cause a global 
collapse in pluripotency gene expression but had a selective and gene-specific impact where 
most pluripotency genes remained unaffected, whereas a minority were either up- or 
downregulated, most to a moderate extent. Many developmental genes in ES cells are 
marked by bivalent chromatin marks49,50 and can be rapidly activated upon differentiation. Of 
2902 bivalent genes, 125 were deregulated within 24 hours of Rad21 deletion. Of these, 
only a minority (48) were upregulated, while 77 were downregulated (Figure 2H). These data 
indicate that cohesin-depleted cells do not undergo wholesale differentiation and corroborate 
the conclusion that cohesin depletion does not result in a collapse of pluripotency gene 
expression. 
 
As cohesin is thought to promote the expression of pluripotency genes by mediating 
enhancer-promoter interactions1- 4 we carefully assessed how acute cohesin depletion 
affected the binding of cohesin to gene regulatory elements and interaction between 
enhancers and promoters in ES cells. ChIP-PCR showed that RAD21 was indeed efficiently 
depleted from the promoters and enhancers of Nanog, Lefty1, and Klf4 (red bars, Figure 2i). 
RAD21 association in differentiating cells is shown for comparison (green bars, Figure 2i). In 
contrast to RAD21, the cohesin loading protein NIPBL remained associated with the 
promoters and enhancers of Nanog, Lefty1 and Klf4 in Rad21-deleted ES cells (red bars, 
Figure 2J). Unexpectedly, Nanog, Lefty1 and Klf4 enhancer-promoter interactions remained 
strong 24 hours after Rad21 deletion as detected by chromatin conformation capture (3C) 
(red bars, Figure 2K), despite reduced cohesin occupancy (red bars, Figure 2i). As a control 
for the ability of our 3C assays to detect change, reduced enhancer-promoter interactions 
	   6	  
were readily detected in differentiating ES cells (green bars, Figure 2K). Hence, in contrast 
to expectations based on ES cells suffering DNA damage, 1 enhancer-promoter interactions 
can be maintained at least at some pluripotency loci even after cohesin depletion. These 
interactions may be mediated by transcription factors, mediator or Nipbl (Figure 3L). 
 
When cohesin-depleted ES cells were allowed to proliferate, significant DNA damage 
occurred within 36 hours as indicated by γ-H2AX (Figure 3A) and upregulation of the p53 
target gene Mdm2 to levels similar to those induced by causing deliberate DNA damage by 
exposure of ES cells to doxorubicin (Figure 3B). After 48 hours of cohesin depletion ES cells 
were arrested in G2/M phase of the cell cycle (Figure 3C). With the exception of Lefty1 the 
expression of the pluripotency genes tested was downregulated (Figure 3D, right) to levels 
that were comparable to those after deliberate DNA damage by exposure to Doxorubicin 
(Figure 3D, centre) or ES cell differentiation induced by withdrawal of 2i (Figure 3D, right). 
These experiments show that (i) proliferation in the absence of cohesin causes DNA 
damage, and that (ii) deliberate DNA damage is sufficient to trigger a collapse of 
pluripotency gene expression in ES cells, reminiscent of what was reported in RNAi screens 
after prolonged depletion of cohesin in proliferating cells. These results are important 
because they question models where cohesin has a universal role in maintaining enhancer-
promoter interactions. 
 
The idea that cohesin has special functions in promoting the expression of pluripotency 
genes is not restricted to the maintenance of pluripotency gene expression in ES cells, but 
extends to the induction of pluripotency gene expression during the reprogramming of 
somatic cells to pluripotency by iPS. 2-4 Given that iPS reprogramming also requires multiple 
rounds of cell division and is sensitive to activation of stress responses 45–47 we wondered to 
what extent the requirement for cohesin in reprogramming reflects essential cohesin 
functions in the cell cycle. We addressed this question by examining early reprogramming 
events that occur when ES cells and somatic cells are fused to form heterokaryons because 
reprogramming in heterokaryons is initiated in the absence of proliferation.51 Interestingly, 
acute cohesin depletion did not impair the ability of ES cells to initiate the expression of 
pluripotency genes in somatic nuclei.41 On the contrary, acutely cohesin-depleted ES cells 
reprogrammed better than control ES cells (Table 1, top). This was explained by the 
expression of Myc, which was increased in cohesin-depleted ES cells in 2i conditions.41 
Increased Myc expression drove increased DNA replication in somatic nuclei, which is 
known to promote reprogramming in ES cell heterokaryons.52 Conversely, cohesin-depleted 
somatic cells showed reduced DNA replication and impaired reprogramming in ES cell 
heterokaryons, but reprogramming was rescued by nuclear transfer experiments in Xenopus 
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oocytes, where reprogramming occurs in the absence of DNA replication.53–55  Taken 
together, these experiments demonstrated that cohesin was not required for the re-
expression of pluripotency genes in somatic nuclei.  
 
To explore how prolonged cohesin depletion and DNA damage affect reprogramming we 
carried out cell fusions between somatic cells and ES cells that were Rad21-deleted 48 
hours earlier and showed DNA damage, cell cycle arrest and reduced pluripotency gene 
expression. These fusions did not result in viable heterokaryon formation or successful 
reprogramming (Table 1, bottom). To explore whether this failure could be ascribed to DNA 
damage we induced deliberate DNA damage by treating ES cells with doxorubicin for 6 
hours prior to fusion with somatic cells. ES cells with DNA damage also failed to form viable 
heterokaryons and did not induce successful reprogramming (Table 1, bottom). 
 
Discussion 
 
We have addressed the role of cohesin in pluripotency and reprogramming. To this end we 
designed experimental systems with the power to separate the spectrum of cohesin 
functions in the cell cycle from cohesin functions in gene regulation. Unexpectedly, cohesin-
depleted ES cells maintained pluripotency gene expression and the ability to reprogram 
somatic nuclei in heterokaryons, provided that ES cells did not incur DNA damage as a 
result of attempting cell division in the absence of cohesin. 41 Data presented in the current 
manuscript show that experimentally induced DNA damage was sufficient to erase 
pluripotency gene expression and to abolish heterokaryon formation and reprogramming. 
These findings affect the interpretation of data from previous studies that had linked cohesin 
with pluripotency and reprogramming where cohesin was depleted over the course of 
several cell divisions. We suggest that results obtained after protracted cohesin depletion 
should not be ascribed to long-range chromosomal interactions or other functions of cohesin 
in transcription. Rather, they should be re-interpreted in the context of essential cohesin 
functions in the maintenance of genome integrity during the cell cycle. 
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Figure legends: 
 
Figure 1: Cohesin functions during the cell cycle. 
A) Cohesin dynamics during the cell cycle (see text for details).  
B) Cohesin depletion in dividing cells can disrupt its cell cycle functions and indirectly impact 
gene expression due to the activation of mitotic checkpoints and cellular stress response 
pathways.  
 
Figure 2: Acute cohesin depletion is compatible with pluripotency gene expression 
and enhancer-promoter interactions. 
A-E) Time course of Rad21 mRNA (A) and RAD21 protein depletion (B) induced by 4’-OHT-
mediated activation of ERt2Cre in ERT2Cre-Rad21lox/lox ES cells (100nM 4’-OHT). Acute 
cohesin depletion did not result in significant DNA damage as indicated by phosphorylation 
of H2AX (γ-H2AX), irradiated ES cells were used as positive control (C); upregulation of the 
p53 target gene Mdm2 (D) or cell cycle arrest (E). 
F) Quantitative RT-PCR analysis of selected pluripotency genes in ES cells before (0h) and 
after acute cohesin depletion (24h). 
G, H) Genome-wide expression analysis of pluripotency genes (G) and bivalent genes (H) in 
acutely cohesin-depleted ES cells at 24 hours. 
I) Chromosome conformation capture (3C) assays for promoter-enhancer interactions at 
Nanog, Lefty1 and Klf4 in control ES cells (black), 24h Rad21-deleted ES cells (red) and 
differentiating ES cells (green). 
J,K) ChIP for RAD21 (I) and NIPBL (J) at the promoters and enhancers of Nanog, Lefty1 and 
Klf4 in control ES cells (black), 24h Rad21-deleted ES cells (red) and differentiating ES cells 
(green). 
L) Enhancer-promoter interactions at pluripotency loci in ES cells (left) are maintained after 
acute cohesin depletion (right, top) but lost during ES cell differentiation (right, bottom). 
 
Figure 3: Incidental or deliberate DNA damage abolishes pluripotency gene 
expression 
A-C) Time course of DNA damage accumulation after cohesin depletion in proliferating ES 
cell indicated by phosphorylation of γ-H2AX (A), expression of the p53 target gene Mdm2 
(B) and cell cycle arrest (C). 
D) Quantitative RT-PCR analysis of selected pluripotency genes in ES cells undergoing 
incidental DNA damage as a result of prolonged cohesin depletion (left), deliberate DNA 
damage inflicted by doxorubicin treatment (6h, middle) or induced differentiation (right). 
	   13	  
 
Table 1. Incidental or deliberate DNA damage abrogates ES cell reprogramming 
potential. 	  
Acutely cohesin-depleted ES cells not only retained the ability to reprogram somatic cells in 
heterokaryons but in addition showed an unexpected increase in their reprogramming 
potential (top, n= 3 biological replicates, 100x106 ES cells per fusion). 41 
Fusion with Rad21 KO (48h) ES cells and doxorubicin-treated (6h) ES cells did not result in 
viable heterokaryon formation or reprogramming. Poor survival meant that lower ES cell 
numbers were available (25x106), and control ES cell numbers were reduced accordingly 
(bottom, n=2 biological replicates per treatment condition). 
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Table 1. Incidental or deliberate DNA damage abrogate ES cell reprogramming potential. 	  
 
ES cells: 
DNA damage: 
Control 
No 
Rad21 ko (24h) 
No 
ES cell # 100x106 100x106 
Somatic cell # 100x106 100x106 
Heterokaryon # ~6x106   * ~6x106   * 
Reprogramming ++ +++ 
 
ES cells: 
DNA damage: 
Control 
No 
Rad21 ko (48h) 
Incidental 
Doxorubicin 
Deliberate 
ES cell # 25x106 25x106 25x106 
Somatic cell # 25x106 25x106 25x106 
Heterokaryon # ~1.5x106   * None None 
Reprogramming ++ N/A N/A 
	  
* Estimate based on 3% fusion efficiency determined by flow cytometry	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